

ZIOPHARM Oncology, Inc. Investor Relations Department One First Ave., Parris Building, # 34 Navy Yard Plaza Boston, MA 02199 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ZIOP	
Last Trade:	6.17
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.11 † (+1.815%)
Day Range	5.97 - 6.19
52-Week Range	4.84 - 7.88
Volume	805,935

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host-disease. Our focus is on the development of cell and viral-therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... (more)

Stock Performance



Press Releases [View all]

Sep 18, 2017

ZIOPHARM Oncology Announces Updated
Findings from Phase 1 Study of Ad-RTS-hIL12 + Veledimex in Recurrent Glioblastoma
Presented at American Academy of
Neurological Surgery Annual Meeting

Sep 5, 2017

ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Sep 1, 2017

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

Jul 31, 2017

ZIOPHARM Oncology Reports Second

Quarter 2017 Financial Results and Provides
Update on Recent Activities

Jul 24, 2017

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

Financials [View all]

Feb 16, 2017 Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

Jul 31, 2017

Quarterly Report (10-Q)

May 1, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)